Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25744952 | 0.89 | ACACB (0.34) | ACACBADRB2LMNAPOLBHTT | |
| SCHEMBL19497528 | 0.79 | ACACB (0.39) | ACACBADRB2LMNAPOLBHTT | |
| SCHEMBL13208426 | 0.79 | POLB (0.40) | ACACBLMNAPOLBHTTL3MBTL1 | |
| SCHEMBL25452970 | 0.78 | NUDT1 (0.37) | ADRB2LMNAPOLBHTTL3MBTL1 | |
| SCHEMBL19497540 | 0.78 | EPHX2 (0.41) | ADRB2LMNAPOLBHTTL3MBTL1 | |
| SCHEMBL16450612 | 0.77 | NUDT1 (0.50) | ACACBLMNAPOLBHTTL3MBTL1 | |
| SCHEMBL20606987 | 0.77 | ACACB (0.38) | ACACB | |
| SCHEMBL15034203 | 0.77 | RXRA (0.42) | ACACBRXRA | |
| SCHEMBL25888662 | 0.76 | GABRP (0.38) | ACACBLMNAPOLBHTTL3MBTL1 | |
| SCHEMBL19343284 | 0.75 | ACACB (0.41) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ACACB 3548/4885ADRB2 262/4885LMNA 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.